Fulcrum Therapeutics Inc (FULC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $287.96M
Last updated: Nov 17, 2026 at 11:05 AM ET
Fulcrum Therapeutics Inc (FULC) Earnings: Report Dates and Results
Fulcrum Therapeutics (FULC) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Fulcrum Therapeutics reported EPS of -$0.11, in line with the -$0.11 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
FULC has an expected report date of Feb 22, 2027.
FULC Earnings Call
The latest FULC earnings call transcript on file is labeled 2026Q1.
Read the 2026Q1 transcriptEarnings History
Of the 29 quarters below that had an estimate, FULC beat 17, missed 11 and matched 1. The widest gap in the table came in the quarter ended Jun 30, 2026, when EPS landed 36.48% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.11 | -$0.11 | -$0.13 - -$0.08 | 0.00% | In line | N/A | 2 | 1 up, 0 down | Nov 12, 2026 | N/A |
| Jun 30, 2026 | -$0.29 | -$0.21 | -$0.31 - -$0.04 | -36.48% | Miss | N/A | 7 | 4 up, 0 down | Jul 30, 2026 | N/A |
| Mar 31, 2026 | -$0.25 | -$0.30 | -$0.38 - -$0.24 | +16.67% | Beat | N/A | 11 | 3 up, 5 down | Apr 27, 2026 | N/A |
| Dec 31, 2025 | -$0.31 | -$0.31 | -$0.33 - -$0.25 | -1.47% | Miss | N/A | 11 | 2 up, 1 down | Feb 24, 2026 | N/A |
| Sep 30, 2025 | -$0.31 | -$0.29 | -$0.34 - -$0.26 | -6.90% | Miss | N/A | 8 | 5 up, 1 down | Oct 29, 2025 | N/A |
| Jun 30, 2025 | -$0.28 | -$0.29 | -$0.31 - -$0.26 | +3.45% | Beat | -132.2% | 8 | 1 up, 0 down | Jul 29, 2025 | N/A |
| Mar 31, 2025 | -$0.28 | -$0.29 | N/A | +3.45% | Beat | N/A | 2 | 0 up, 1 down | May 1, 2025 | N/A |
| Dec 31, 2024 | -$0.31 | -$0.29 | -$0.34 - -$0.23 | -7.53% | Miss | N/A | 6 | 4 up, 2 down | Feb 25, 2025 | N/A |
| Sep 30, 2024 | -$0.46 | -$0.40 | -$0.47 - -$0.37 | -15.00% | Miss | N/A | 9 | 0 up, 0 down | Nov 13, 2024 | N/A |
| Jun 30, 2024 | $0.87 | $0.06 | -$0.46 - $0.74 | N/A | N/A | N/A | 8 | 0 up, 0 down | Jul 31, 2024 | $80.00M |
| Mar 31, 2024 | -$0.43 | -$0.44 | -$0.46 - -$0.39 | +2.27% | Beat | N/A | 8 | 0 up, 0 down | May 13, 2024 | N/A |
| Dec 31, 2023 | -$0.40 | -$0.43 | -$0.50 - -$0.38 | +6.98% | Beat | N/A | 7 | 0 up, 0 down | Feb 27, 2024 | $871000 |
| Sep 30, 2023 | -$0.39 | -$0.44 | -$0.46 - -$0.39 | +11.36% | Beat | N/A | 6 | 1 up, 0 down | Nov 7, 2023 | $759000 |
| Jun 30, 2023 | -$0.38 | -$0.44 | -$0.48 - -$0.39 | +13.64% | Beat | N/A | 7 | 0 up, 0 down | Aug 3, 2023 | $880000 |
| Mar 31, 2023 | -$0.41 | -$0.46 | -$0.55 - -$0.39 | +10.87% | Beat | N/A | 8 | 0 up, 0 down | May 15, 2023 | $295000 |
| Dec 31, 2022 | -$0.50 | -$0.49 | -$0.53 - -$0.41 | -2.04% | Miss | N/A | 9 | 0 up, 1 down | Mar 9, 2023 | $685000 |
| Sep 30, 2022 | -$0.50 | -$0.61 | -$0.74 - -$0.47 | +18.03% | Beat | N/A | 8 | 1 up, 0 down | Nov 8, 2022 | $1.18M |
| Jun 30, 2022 | -$0.83 | -$0.66 | -$0.74 - -$0.58 | -25.76% | Miss | N/A | 8 | 0 up, 0 down | Aug 11, 2022 | $1.88M |
| Mar 31, 2022 | -$0.64 | -$0.63 | -$0.74 - -$0.57 | -1.59% | Miss | N/A | 8 | 0 up, 0 down | May 9, 2022 | $2.59M |
| Dec 31, 2021 | -$0.58 | -$0.73 | -$1.13 - -$0.54 | +20.55% | Beat | N/A | 7 | 0 up, 0 down | Mar 3, 2022 | $5.06M |
| Sep 30, 2021 | -$0.57 | -$0.65 | -$0.74 - -$0.57 | +12.31% | Beat | N/A | 7 | 6 up, 0 down | Nov 4, 2021 | $4.93M |
| Jun 30, 2021 | -$0.60 | -$0.65 | -$0.69 - -$0.56 | +7.69% | Beat | N/A | 6 | N/A | Aug 10, 2021 | $4.38M |
| Mar 31, 2021 | -$0.54 | -$0.66 | -$0.70 - -$0.62 | +18.18% | Beat | N/A | 6 | N/A | May 6, 2021 | $4.79M |
| Dec 31, 2020 | -$0.64 | -$0.72 | -$0.77 - -$0.69 | +11.11% | Beat | N/A | 6 | N/A | Mar 4, 2021 | $4.22M |
| Sep 30, 2020 | -$0.70 | -$0.64 | -$0.75 - -$0.59 | -9.38% | Miss | N/A | 6 | N/A | Nov 10, 2020 | $1.85M |
| Jun 30, 2020 | -$0.66 | -$0.75 | -$0.95 - -$0.68 | +12.00% | Beat | N/A | 5 | N/A | Aug 11, 2020 | $2.00M |
| Mar 31, 2020 | -$0.81 | -$0.75 | -$0.82 - -$0.70 | -8.00% | Miss | N/A | 3 | N/A | May 13, 2020 | $750000 |
| Dec 31, 2019 | -$0.71 | -$0.88 | -$1.05 - -$0.69 | +19.32% | Beat | N/A | 4 | N/A | Mar 5, 2020 | N/A |
| Sep 30, 2019 | -$0.97 | -$0.72 | -$10.05 - -$0.42 | -34.72% | Miss | N/A | 4 | N/A | Nov 14, 2019 | N/A |
| Jun 30, 2019 | -$0.71 | -$0.75 | -$5.45 - -$0.75 | +5.33% | Beat | N/A | 2 | N/A | Aug 26, 2019 | N/A |
| Mar 31, 2019 | -$0.31 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 29, 2019 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.18, after -$0.33 the year before. It was -$2.70 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.18 | N/A |
| Dec 31, 2024 | -$0.33 | N/A |
| Dec 31, 2023 | -$1.58 | N/A |
| Dec 31, 2022 | -$2.47 | N/A |
| Dec 31, 2021 | -$2.29 | N/A |
| Dec 31, 2020 | -$2.81 | N/A |
| Dec 31, 2019 | -$2.70 | N/A |
Earnings Calls
The 7 most recent earnings calls are listed below; the latest, 2026Q1 for the period ended Mar 31, 2026, runs about 5,000 words across 11 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q1 | Mar 31, 2026 | 4,993 | 11 | |
| 2025Q4 | Dec 31, 2025 | 7,099 | 12 | |
| 2025Q3 | Sep 30, 2025 | 5,421 | 12 | |
| 2025Q1 | Mar 31, 2025 | 4,127 | 9 | |
| 2024Q4 | Dec 31, 2024 | 5,787 | 10 | |
| 2024Q3 | Sep 30, 2024 | 5,072 | 12 | |
| 2024Q2 | Jun 30, 2024 | 4,851 | 10 |
2026Q1 Earnings Call
Opening remarks
Alexander Sapir Chief Executive Officer & President That's great. Thanks, Shannon, and good morning, everyone. We appreciate you all joining us today. The first quarter of 2026 was an important and exciting period for Fulcrum highlighted by the positive clinical data we reported from the Phase Ib PIONEER trial of pociredir in sickle cell disease. Now as a reminder, sickle cell disease is a serious genetic blood disorder with a significant unmet need, affecting approximately 120,000 patients in the United States and millions more globally. Patients with sickle cell disease face a substantial disease burden, including chronic pain and fatigue as well as serious complications, such as vaso-occlusive crises, stroke and progressive end organ damage, all of which result in a substantial reduction in life expectancy of over 20 years. Now we have known for decades that increasing levels of fetal hemoglobin, or HbF, in patients with sickle cell disease leads to improvements in anemia and reductions in vaso-occlusive pain crises. And so it was for that reason that we were so pleased with the data that we reported in February, demonstrating that after only 12 weeks of treatment, 20 milligrams of pociredir taken once daily demonstrated a robust and clinically meaningful increase in HbF from 7.1% at baseline to 19.3% at week 12, along with improvements in markers of hemolysis and improvements in anemia. We also observed continued progression toward pancellular expression of HbF, which we believe is critical for achieving meaningful clinical benefit. And importantly, we saw a reduction in the number of VOCs we would have expected in this severe patient population with 7 of the 12 patients experiencing no VOCs during the 12-week treatment period. And importantly, pociredir has continued to be generally well tolerated with no treatment-related serious adverse events reported to date. And so taken together, these data reinforce our conviction in pociredir's potential to address the underlying biology of sickle cell disease and support our belief that pociredir has the potential to represent a differentiated, once-daily oral treatment option for patients. Now during the quarter, we also initiated an open-label, long-term dosing trial for patients in the PIONEER study, and we recently enrolled our first patient in this new study. All patients in this long-term dosing study previously completed 12 weeks of treatment as part of the PIONEER trial. Therefore, we expect this study to provide a distinct data set offering important insights into long-term safety, durability of response and the effects of reinitiating treatment with pociredir.
Frequently Asked Questions About FULC
When is Fulcrum Therapeutics's next earnings date?
Fulcrum Therapeutics's next earnings report is expected for Feb 22, 2027.
Did FULC beat earnings estimates last quarter?
Fulcrum Therapeutics reported EPS of -$0.11 for the quarter ended Sep 30, 2026, in line with the -$0.11 estimate.
What EPS do analysts expect from FULC next quarter?
The consensus EPS estimate for Fulcrum Therapeutics for the quarter ending Dec 31, 2026 is -$0.10 from 8 analysts, with estimates from -$0.30 to -$0.02.
How often does FULC beat earnings estimates?
Fulcrum Therapeutics beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -3.60%.
FULC pages: Overview, Earnings, Forecast, Financials, Competitors